Buserelin vs Leuprolide
A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility
A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Buserelin
200–200 mcg
Leuprolide
1–1 mg
Frequency
Buserelin
Once daily
Leuprolide
Once daily
Administration
Buserelin
Subcutaneous injection
Leuprolide
Subcutaneous injection (daily)
Cycle length
Buserelin
Ongoing/indefinite
Leuprolide
Ongoing/indefinite
Onset speed
Buserelin
Moderate (1-2 weeks)
Leuprolide
Moderate (1-2 weeks)
Evidence level
Buserelin
Strong human trials (Phase 3 or FDA approved)
Leuprolide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Hormone Suppression
Cancer Management
Fertility Support
Endometriosis & Fibroid Relief
Hormone Control
Compound specifications
Buserelin
Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6
Leuprolide
Molecular formula
C59H84N16O12
Molecular weight
1209.4 g/mol
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~95% (subcutaneous injection)
CAS number
74381-53-6
Dosing compared
Buserelin
Subcutaneous
500 mcg
Every 8 hours (3 times daily) · First 7 days
The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
200 mcg
Once daily · Ongoing maintenance
After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].
Intranasal
400 mcg (2 sprays per nostril)
3 times daily (1,200 mcg/day) · Ongoing maintenance
The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].
Implant
6.3 mg
Once every 2 months · Long-term
A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
9.45 mg
Once every 3 months · Long-term
A larger implant lasts about 3 months between placements [5].
Leuprolide
Subcutaneous
1 mg
Once daily · Ongoing
The original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].
Intramuscular
7.5 mg
Every month · Ongoing
The 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
22.5 mg
Every 3 months · Ongoing
The 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
30-45 mg
Every 4-6 months · Ongoing
The longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].
Best suited for
Buserelin
Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Leuprolide
Managing advanced or metastatic prostate cancer
Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
Controlling severe endometriosis pain
Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Treating symptomatic uterine fibroids
Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Delaying early puberty in children
Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Side effects
Buserelin
Leuprolide
Common
- Hot flashes (very common in men)
- Decreased libido and erectile dysfunction
- Injection site pain or swelling
- Nausea
- Fatigue
- Mood changes or depression
- Joint or muscle pain
- Headaches
- Dizziness
- Thinning hair
- Decreased bone density (osteoporosis with long-term use)
- QT prolongation (rare but serious cardiac effect)
- Tumor flare (temporary worsening of cancer symptoms in first weeks)
- Severe allergic reactions
- Spinal cord compression risk in men with metastatic disease
Serious
- Severe allergic reaction
Safety & evidence
Buserelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for other use
Safety overview
Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.
Contraindications
- Pregnancy or breastfeeding
- Hypersensitivity to GnRH agonists
- Certain bone diseases when long-term use is planned
Leuprolide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]
Contraindications
- Pregnancy or breastfeeding (teratogenic)
- Undiagnosed vaginal bleeding
- Active bone metastases with spinal cord compression (increased fracture risk)
- Allergy to GnRH agonists or components
- Severe cardiovascular disease with QT prolongation risk
Which is right for you?
Choose Buserelin if...
- Managing advanced prostate cancer
- Treating endometriosis and reducing associated pain
- Optimizing ovarian response during fertility treatments
Choose Leuprolide if...
- Managing advanced or metastatic prostate cancer
- Controlling severe endometriosis pain
- Treating symptomatic uterine fibroids
- Delaying early puberty in children